Results 61 to 70 of about 37,664 (239)

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma

Cancer Discovery, 2021
We conducted next generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree.
J. Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, H. Gupta, D. Rubinson, Isobel J. Fetter, J. Hornick, J. Nowak, G. Siravegna, L. Goyal, Lei Shi, L. Brais, M. Loftus, A. Shinagare, T. Abrams, T. Clancy, Jiping Wang, Anuj K. Patel, F. Brichory, Anne Vaslin Chessex, R. Sullivan, Rachel B. Keller, Sarah L. Denning, E. Hill, G. Shapiro, A. Pokorska-Bocci, C. Zanna, K. Ng, D. Schrag, P. Janne, W. Hahn, A. Cherniack, R. Corcoran, M. Meyerson, Antoine Daina, V. Zoete, N. Bardeesy, B. Wolpin   +39 more
semanticscholar   +1 more source

Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2

Cell Death and Disease
Cisplatin (DDP)-based chemoradiotherapy is one of the standard treatments for nasopharyngeal carcinoma (NPC). However, the sensitivity and side effects of DDP to patients remain major obstacles for NPC treatment.
Feng Liu, Ling Tang, Huai Liu, Yanzhu Chen, Tengfei Xiao, Wan-Yi Gu, Hongmin Yang, Hui Wang, Pan Chen   +8 more
semanticscholar   +1 more source

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Clinical Cancer Research, 2021
Purpose: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co ...
Tomoko Jogo, Y. Nakamura, K. Shitara, H. Bando, H. Yasui, T. Esaki, T. Terazawa, T. Satoh, E. Shinozaki, T. Nishina, Y. Sunakawa, Y. Komatsu, H. Hara, E. Oki, N. Matsuhashi, T. Ohta, Takeshi Kato, K. Ohtsubo, T. Kawakami, N. Okano, Yoshiyuki Yamamoto, T. Yamada, A. Tsuji, J. Odegaard, H. Taniguchi, T. Doi, S. Fujii, T. Yoshino   +27 more
semanticscholar   +1 more source

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy

Clinical Cancer Research
Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers
Alberto Gonzalez-Medina, M. Vila-Casadesús, M. Gómez-Rey, C. Fabregat-Franco, Alexandre Sierra, Tian V. Tian, F. Castet, Gloria Castillo, J. Matito, P. Martinez, J. Miquel, P. Nuciforo, R. Pérez-López, T. Macarulla, A. Vivancos   +14 more
semanticscholar   +1 more source

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting

Cancer Management and Research, 2021
Massimiliano Salati,1,2 Francesco Caputo,1 Cinzia Baldessari,1 Pietro Carotenuto,3 Marco Messina,4 Stefania Caramaschi,5 Massimo Dominici,1 Luca Reggiani Bonetti5 1Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 2PhD ...
Salati M, Caputo F, Baldessari C, Carotenuto P, Messina M, Caramaschi S, Dominici M, Bonetti LR   +7 more
doaj  

Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene

Cells, 2023
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but
Garima Dixit, Benjamin A. Pappas, Gourav Bhardwaj, Willow Schanz, Thorsten Maretzky   +4 more
doaj   +1 more source

Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies

Clinical Cancer Research
Purpose Understanding resistance to selective FGFR inhibitors is crucial to improve the clinical outcomes of patients with FGFR2-driven malignancies.
F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur, R. Bahleda, L. Bigot, Rémy Barbé, Catline Nobre, D. Combarel, S. Michiels, A. Italiano, C. Smolenschi, L. Tselikas, J. Scoazec, Santiago Ponce-Aix, Benjamin Besse, F. André, K. Olaussen, A. Hollebecque, L. Friboulet   +19 more
semanticscholar   +1 more source

Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations

JCO Precision Oncology, 2021
PURPOSE Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond.
A. Varghese, J. Patel, Y. Janjigian, Fanli Meng, S. D. Selcuklu, G. Iyer, B. Houck-Loomis, J. Harding, E. O’Reilly, G. Abou-Alfa, M. Lowery, M. Berger   +11 more
semanticscholar   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Deep Contrastive Learning for High‐Throughput Prediction of Drug Resistance Mutations from Sequences

Advanced Science, EarlyView.
This study presents DeepMutDTA, a deep learning framework aimed at predicting mutation‐induced changes in protein‐drug interactions and prioritizing variants potentially linked to drug resistance. Trained on large‐scale data, it incorporates SimSiam‐MuTF, a label‐aware contrastive fine‐tuning strategy that encourages separation between WT and MT ...
Xiaowen Hu, Pan Zhang, Shangqian Wu, Hao Sun, Minwei Li, Sophia Tsoka, Zizhang Sheng, Lei Deng   +7 more
wiley   +1 more source